It's been a tough session for the market. After a weak lead from Wall Street overnight, the ASX 200 is down around 1.55% at the time of writing on Thursday. That takes losses for March to roughly 7.5%, which is a meaningful pullback in such a short period.
Whenever markets fall like this, quality stocks tend to get dragged down with everything else.
That's exactly what we're seeing right now, with several well-known ASX 200 stocks hitting 52-week lows. The key question is: is this an opportunity for investors?
Here's how I'm thinking about it.
CSL Ltd (ASX: CSL)
CSL has been under pressure for a while now, and this latest selloff has pushed it to fresh lows.
Sentiment has clearly turned cautious, but I don't think the long-term story has changed in any meaningful way.
This is still one of Australia's highest-quality healthcare companies, with global scale, strong margins, and a long track record of innovation.
Short-term earnings noise and investor concerns can move the share price around, but over time, businesses like CSL tend to reflect their underlying quality.
For me, this looks more like a temporary valuation reset than a structural problem.
Aristocrat Leisure Ltd (ASX: ALL)
Aristocrat has also been caught up in the broader tech sell-off, with concerns around artificial intelligence (AI) disruption weighing on sentiment.
That's understandable, but I think it may be overstated.
The company has a strong position in gaming content, world-class IP, and a growing digital segment, which gives it multiple avenues for growth.
It has also shown an ability to adapt over time, whether that's through new game development or expanding into adjacent markets.
With the share price now significantly below its highs, I think the risk-reward is starting to look more attractive.
Cochlear Ltd (ASX: COH)
Cochlear isn't the kind of company that usually trades at 52-week lows.
It's a global leader in implantable hearing solutions, with a strong brand and significant pricing power.
Like CSL, it has been dragged lower by broader market weakness rather than a clear deterioration in its long-term outlook.
Demand for its products is supported by ageing populations and increasing awareness of hearing health, which gives it a structural growth tailwind.
When high-quality healthcare names like this fall sharply, I tend to take notice.
Amcor plc (ASX: AMC)
Amcor is a very different type of business to the others, but it's also worth a look at these levels.
Packaging may not be exciting, but it is essential.
Amcor operates globally, generates steady cash flow, and pays attractive dividends. That combination can be valuable during periods of market uncertainty.
Its shares have come under pressure alongside the broader market, but the underlying business remains resilient.
For income-focused investors, this kind of pullback can create an opportunity to lock in a higher yield.
Should you buy the dip?
Market selloffs can feel uncomfortable in the moment. But they're also when some of the best long-term opportunities are created.
CSL, Aristocrat, Cochlear, and Amcor are established, high-quality ASX 200 stocks that are now trading at much lower prices than they were not long ago.
That doesn't guarantee they'll rebound immediately. Volatility could continue, especially if global markets remain under pressure.
But for long-term investors, I think this kind of weakness is worth leaning into rather than fearing.
Foolish takeaway
Sharp market declines often pull down both weak and strong companies at the same time.
Right now, I think that is creating opportunities in several ASX 200 stocks that don't often trade at these kinds of levels.
CSL, Aristocrat, Cochlear, and Amcor all have challenges, but they also have strong long-term fundamentals.
For me, this looks less like a reason to panic and more like a chance to start building or adding to positions in quality businesses.
The post CSL and these ASX 200 stocks just hit 52-week lows: Should you buy the dip? appeared first on The Motley Fool Australia.
Motley Fool contributor Grace Alvino has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has positions in and has recommended Amcor Plc. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026